| Annual Financials | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
Revenue  | 107 | 100 | 108 | 113 | 156 | 169 | 183 | 202 | 190 | 198 | 160 | 182 |
| Expenses | 98 | 94 | 101 | 105 | 138 | 148 | 159 | 194 | 182 | 186 | 152 | 166 |
| EBITDA | 8 | 6 | 7 | 8 | 18 | 21 | 24 | 9 | 8 | 12 | 8 | 16 |
| Operating Profit % | 7 % | 6 % | 6 % | 6 % | 11 % | 12 % | 13 % | 3 % | 1 % | 6 % | 5 % | 9 % |
| Depreciation | 3 | 3 | 2 | 3 | 3 | 3 | 3 | 4 | 5 | 6 | 6 | 6 |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 6 | 5 | 5 |
| Profit Before Tax | 2 | 0 | 2 | 2 | 12 | 14 | 17 | 2 | 0 | 1 | -3 | 5 |
| Tax | 0 | 0 | 0 | 1 | 5 | 3 | 4 | 1 | 0 | 1 | -2 | 0 |
| Net Profit | 2 | 0 | 1 | 2 | 8 | 11 | 14 | 1 | -0 | 0 | -1 | 6 |
| EPS in ₹ | 1.78 | 0.54 | 1.69 | 2.14 | 9.39 | 13.62 | 17.14 | 1.43 | -0.23 | 0.17 | -2.97 | 6.80 |
Everest Organics
Everest Organics
389.55
-20.45
(-4.99%)
Key Fundamentals
Market Cap
398.10 Cr
EPS
-2.97
PE Ratio
61.48
Dividend Yield
0.00 %
Industry
Healthcare 52 Week High
477.00
52 Week Low
112.50
PB Ratio
5.53
Debt to Equity
0.91
Sector
Pharmaceuticals Actual
Company News
View All News
Everest Organics Board Approves Re-appointment of Key Directors and New Company Secretary
Aug 05, 2025
Aug 05, 2025Everest Organics Limited's Board of Directors approved the re-appointment of Dr. Srikakarlapudi Sirisha as Managing Director for three years from August 10, 2025 to August 09, 2028, and Mr. Srikakarlapudi Harikrishna as Whole-time Director for three years from September 25, 2025 to September 24, 2028. Both appointments are subject to shareholder approval at the 32nd Annual General Meeting. The board also appointed Ms. Shweta Singh as Company Secretary and Compliance Officer effective August 05, 2025. Dr. Sirisha, 48, holds M.B.B.S and MD degrees and has been with the company since 2014, also serving as CEO. Mr. Harikrishna, 46, is a mechanical engineer who joined in 2007 and brings expertise in project planning and engineering. Both directors are promoters and related to each other. Ms. Singh is an associate member of the Institute of Company Secretaries of India with over 3 years of compliance experience.
Everest Organics Reports Quarterly Profit of Rs 140.52 Lakhs, Board Approves Key Management AppointmentsAug 05, 2025
Aug 05, 2025Everest Organics Limited reported a profit of Rs 140.52 lakhs for the quarter ended June 30, 2025, compared to a loss of Rs 608.96 lakhs in the same quarter last year. Revenue from operations stood at Rs 5,381.32 lakhs, comprising domestic turnover of Rs 4,215.33 lakhs and export turnover of Rs 1,165.99 lakhs. The company operates in Active Pharmaceutical Ingredients (API) and their intermediates segment. The Board approved the re-appointment of Dr. Srikakarlapudi Sirisha as Managing Director and Mr. Srikakarlapudi Harikrishna as Whole-time Director, subject to shareholder approval. Ms. Shweta Singh was appointed as Company Secretary and Compliance Officer. The company scheduled its 32nd Annual General Meeting for September 27, 2025. The auditors issued a qualified review report citing concerns about the company operating at enhanced production levels without necessary approvals from Telangana State Pollution Control Board, which could impact its going concern status.
Everest Organics Receives Korean Drug Master File Approval for Rabeprazole Sodium APIFeb 18, 2025
Everest Organics has obtained Drug Master File (DMF) approval from Korean authorities for its Rabeprazole Sodium Active Pharmaceutical Ingredient (API). This approval is significant as it allows the company to market and sell this API in the Korean pharmaceutical market, potentially expanding its international presence and revenue streams.
Peer Comparison Compare Peers on Screener
Competitors | LTP | Market Cap (₹ Cr.) | P/E Ratio | Revenue (₹ Cr.) | YoY Revenue Growth % | Net Profit (₹ Cr.) | YoY Profit Growth % | RSI |
|---|---|---|---|---|---|---|---|---|
1,679.10 | #1 3,98,049.70 | 38.75 | #1 54,729.00 | 9.71 | #1 10,980 | -19.84 | 61.71 | |
6,621.50 | 1,75,222.50 | 76.19 | 9,712.00 | 18.67 | 2,191 | 26.74 | 72.60 | |
1,577.60 | 1,26,768.90 | 23.67 | 28,409.50 | 7.12 | 5,291 | 9.88 | 60.63 | |
3,584.30 | 1,19,599.80 | 60.49 | 11,539.40 | 6.99 | 1,911 | 19.91 | 53.74 | |
1,255.90 | 1,03,508.80 | #1 18.25 | 33,741.20 | 16.73 | 5,725 | 1.26 | 48.97 | |
2,476.60 | 1,01,344.60 | 53.48 | 12,744.20 | #1 20.90 | 2,007 | -18.14 | 47.04 | |
987.65 | 99,073.80 | 21.09 | 23,511.00 | 18.55 | 4,615 | 2.60 | 45.37 | |
1,940.00 | 89,121.90 | 23.79 | 22,909.50 | 13.74 | 3,306 | #1 51.64 | 46.82 | |
5,581.50 | 66,047.70 | 28.61 | 13,458.30 | 3.70 | 2,216 | 21.39 | 63.11 | |
1,101.00 | 64,254.10 | 19.04 | 32,345.60 | 9.43 | 3,484 | -10.24 | 50.87 |
Growth Rate
Revenue Growth
-19.13 %
Net Income Growth
-1,400.00 %
Cash Flow Change
-133.44 %
ROE
-713.33 %
ROCE
-74.78 %
EBITDA Margin (Avg.)
-17.53 %
Yearly Financial Results
Balance Sheet
| Balance Sheet | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Total Assets | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 225 |
| Fixed Assets | 24 | 27 | 33 | 34 | 39 | 39 | 44 | 49 | 55 | 54 | 50 |
| Current Assets | 42 | 47 | 49 | 58 | 67 | 79 | 89 | 118 | 133 | 149 | 148 |
| Capital Work in Progress | 0 | 1 | 1 | 1 | 0 | 1 | 0 | 8 | 12 | 19 | 23 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 43 | 47 | 52 | 60 | 69 | 80 | 92 | 121 | 136 | 153 | 152 |
| Total Liabilities | 67 | 76 | 86 | 94 | 107 | 120 | 135 | 178 | 202 | 227 | 225 |
| Current Liabilities | 50 | 56 | 63 | 67 | 71 | 74 | 77 | 113 | 138 | 160 | 140 |
| Non Current Liabilities | 11 | 14 | 7 | 8 | 10 | 12 | 11 | 19 | 18 | 21 | 15 |
| Total Equity | 6 | 6 | 16 | 19 | 26 | 34 | 47 | 47 | 46 | 46 | 70 |
| Reserve & Surplus | -4 | 3 | 8 | 11 | 18 | 26 | 39 | 39 | 38 | 38 | 59 |
| Share Capital | 9 | 3 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 8 | 10 |
Cash Flow
| Cash Flow | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
| Net Cash Flow | 0 | 0 | 0 | -0 | 1 | 0 | -0 | -1 | 0 | 0 | 6 |
| Investing Activities | -3 | -7 | -8 | -4 | -5 | -6 | -12 | -17 | -16 | -13 | -5 |
| Operating Activities | 4 | 7 | 10 | 5 | 9 | 10 | 14 | 14 | 18 | 16 | -5 |
| Financing Activities | -2 | -0 | -2 | -1 | -3 | -3 | -2 | 2 | -3 | -3 | 16 |
Share Holding
| % Holding | Mar 2021 | Jun 2021 | Sept 2021 | Dec 2021 | Mar 2022 | Jun 2022 | Sept 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sept 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sept 2024 | Dec 2024 | Jan 2025 | Mar 2025 | Jun 2025 |
| Promoter | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 74.15 % | 61.09 % | 61.09 % | 60.99 % |
| FIIs | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| DIIs | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.03 % | 0.06 % | 0.06 % | 0.05 % | 0.05 % | 0.02 % | 0.02 % | 0.02 % |
| Government | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % | 0.00 % |
| Public / Retail | 19.04 % | 18.48 % | 18.27 % | 18.84 % | 18.91 % | 19.27 % | 19.29 % | 19.38 % | 19.40 % | 19.41 % | 19.60 % | 19.99 % | 20.00 % | 20.05 % | 20.13 % | 18.63 % | 32.22 % | 23.87 % | 25.35 % |
| Others | 6.78 % | 7.34 % | 7.56 % | 6.99 % | 6.91 % | 6.55 % | 6.53 % | 6.44 % | 6.42 % | 6.41 % | 6.22 % | 5.83 % | 5.79 % | 5.75 % | 5.67 % | 7.17 % | 6.67 % | 15.02 % | 13.64 % |
| No of Share Holders | 8,122 | 11,174 | 10,784 | 11,135 | 11,154 | 11,244 | 11,250 | 11,100 | 10,834 | 10,634 | 10,494 | 10,242 | 10,023 | 9,792 | 9,996 | 9,326 | 8,795 | 8,756 | 8,281 |
Dividend History
| Annual Cash Flows | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Per Share (₹) | 0.00 | 0.00 | 0.00 | 1 | 1 | 1.5 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend Yield (%) | 0.00 | 0.00 | 0.00 | 1.05 | 0.43 | 0.86 | 0.00 | 0.00 | 0.00 | 0.00 |
Corporate Action
| Record Date | Corporate Action | Information | Announcement Day | LTP at Annoucement | LTP at Record Day |
|---|---|---|---|---|---|
| 18 Feb 2021 |  Dividend | ₹ 0.50 /share | 17 Feb 2021 | 265.65 | 241.25 |
| 11 Sept 2021 | Dividend | ₹ 1.00 /share | 08 Sept 2021 | 382.00 | 317.95 |
| 17 Sept 2022 | Dividend | ₹ 0.50 /share | 15 Sept 2022 | 152.15 | 142.95 |
| 27 Sept 2024 |  Annual General Meeting | NA | 27 Sept 2024 | 138.90 | 134.20 |
| 13 Nov 2024 |  Quarterly Result Announcement | NA | 13 Nov 2024 | 123.15 | 114.85 |
| 08 Jan 2025 |  Extraordinary General Meeting | NA | 08 Jan 2025 | 211.95 | 289.00 |
| 11 Feb 2025 | Quarterly Result Announcement | NA | 11 Feb 2025 | 262.80 | 264.80 |
| 27 May 2025 | Quarterly Result Announcement | NA | 27 May 2025 | 418.70 | 449.75 |
| 05 Aug 2025 | Quarterly Result Announcement | NA | 05 Aug 2025 | 340.75 | 320.50 |
| 27 Sept 2025 | Annual General Meeting | NA | 27 Sept 2025 | 320.50 | 403.60 |
Announcements
General Update-Monthly Report On Special Window For Re-Lodgement Of Transfer Request Of Physical Shares For The Month Of October2025.Oct 08, 2025
Oct 08, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Oct 08, 2025
Oct 08, 2025Special Window For Re-Lodgement Of Transfer Requests Of Physical Shares .Oct 03, 2025
Oct 03, 2025Shareholder Meeting / Postal Ballot-Scrutinizers ReportSep 29, 2025
Sep 29, 2025Proceeding Of 32Nd Annual General Meeting Of The Everest Organics Limited Held On 27Th September 2025 At 03.00 P.M Through Video Conferencing (VC).Sep 27, 2025
Sep 27, 2025Closure of Trading WindowSep 20, 2025
Sep 20, 2025General- Update- Monthly Report On Special Window Re-Lodgement Of Shares For The Month Of August2025.Sep 19, 2025
Sep 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 19, 2025
Sep 19, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationSep 06, 2025
Sep 06, 2025Letter To MembersSep 05, 2025
Sep 05, 2025Reg. 34 (1) Annual Report.Sep 04, 2025
Sep 04, 202532Nd Annual General Meeting -NoticeSep 04, 2025
Sep 04, 2025General Updates-Newspaper PublicationAug 30, 2025
Aug 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationAug 08, 2025
Aug 08, 2025Appointment of Company Secretary and Compliance OfficerAug 05, 2025
Aug 05, 2025Announcement under Regulation 30 (LODR)-Change in ManagementAug 05, 2025
Aug 05, 2025Financial Results For Quarter Ended June 30 2025.Aug 05, 2025
Aug 05, 2025Board Meeting Outcome for Outcome Of Board Meeting Held On August 05 2025 For Quarter Ended June 30 2025Aug 05, 2025
Aug 05, 2025Board Meeting Intimation for 1. Unaudited Financial Results Along With Limited Review Report For Quarter Ended June 30 2025 .
2. Other Business Transactions.Jul 28, 2025
Jul 28, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jul 15, 2025
Jul 15, 2025Issue Of Duplicate Share CertificateJul 14, 2025
Jul 14, 2025Closure of Trading WindowJun 27, 2025
Jun 27, 2025Compliances-Reg.24(A)-Annual Secretarial ComplianceMay 30, 2025
May 30, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationMay 30, 2025
May 30, 2025Appointment Of AuditorsMay 28, 2025
May 28, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held From May 27 2025 To May 28 2025.May 28, 2025
May 28, 2025Audited Financial Results For The Quarter And Financial Year Ended March 31 2025May 28, 2025
May 28, 2025Board Meeting Intimation for Considering Inter Alia The Audited Financial Results And Statements For The Quarter And Year Ended March 31 2025May 21, 2025
May 21, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Apr 09, 2025
Apr 09, 2025Announcement under Regulation 30 (LODR)-Change in Corporate Office AddressApr 04, 2025
Apr 04, 2025Announcement under Regulation 30 (LODR)-Resignation of Company Secretary / Compliance OfficerMar 27, 2025
Mar 27, 2025Closure of Trading WindowMar 24, 2025
Mar 24, 2025Receipt Of Trading Approval From BSE LimitedMar 20, 2025
Mar 20, 2025Receipt Of Listing Approval From BSE LimitedMar 12, 2025
Mar 12, 2025Intimation Of Korea Drug Master File (KDMF) Approval For CompanyS Rabeprazole Sodium APIFeb 18, 2025
Feb 18, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationFeb 13, 2025
Feb 13, 2025 Shareholder Meeting / Postal Ballot-Scrutinizer"s ReportFeb 13, 2025
Feb 13, 2025Shareholder Meeting / Postal Ballot-Outcome of Postal_BallotFeb 13, 2025
Feb 13, 2025Integrated Filing (Financial)Feb 11, 2025
Feb 11, 2025Board Meeting Outcome for Outcome Of The Board Meeting Held TodayFeb 11, 2025
Feb 11, 2025Un-Audited Financial Results For The Quarter And Nine Months Ended December 31 2024.Feb 11, 2025
Feb 11, 2025Board Meeting Intimation for Board Meeting Scheduled To Be Held On Tuesday February 11 2025.Feb 05, 2025
Feb 05, 2025Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018Jan 22, 2025
Jan 22, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 15, 2025
Jan 15, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 15, 2025
Jan 15, 2025Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011Jan 15, 2025
Jan 15, 2025Announcement under Regulation 30 (LODR)-Newspaper PublicationJan 14, 2025
Jan 14, 2025Certificate From Statutory Auditor In Terms Of Regulation 169(4) & (5) Of The SEBI (ICDR) Regulations 2018Jan 13, 2025
Jan 13, 2025Shareholder Meeting / Postal Ballot-Notice of Postal BallotJan 13, 2025
Jan 13, 2025Announcement under Regulation 30 (LODR)-Change in ManagementJan 13, 2025
Jan 13, 2025Technical Indicators
RSI(14)
Neutral 47.99
ATR(14)
Less Volatile 18.79
STOCH(9,6)
Neutral 58.18
STOCH RSI(14)
Neutral 44.72
MACD(12,26)
Bearish -1.11
ADX(14)
Weak Trend 12.90
UO(9)
Bearish 61.65
ROC(12)
Downtrend And Accelerating -3.16
WillR(14)
Neutral -59.91
we are part of Raise Financial Services
built with love
for indians who love to invest & trade
Market Community
Follow us on
